420846-72-6

Basic information

• Product Name: 3-((4-Oxo-3,4-dihydrophthalazin-1-yl)methyl)benzoic acid
• Synonyms: 3-((4-Oxo-3,4-dihydrophthalazin-1-yl)methyl)benzoic acid;Benzoic acid, 3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-;3-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]benzoic acid;3-[(4-Oxo-3,4-dihydro-1-phthalazinyl)methyl]benzoic acid;Olaparib Impurity 14
• CAS NO: 420846-72-6
• Molecular Formula: C₁₆H₁₂N₂O₃
• Molecular Weight: 280.27808
• Mol File: 420846-72-6.mol

Chemical Properties

• Appearance: /
• Density: 1.36±0.1 g/cm3(Predicted)
• PKA: 4.12±0.10(Predicted)
• CAS DataBase Reference: 3-((4-Oxo-3,4-dihydrophthalazin-1-yl)methyl)benzoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 3-((4-Oxo-3,4-dihydrophthalazin-1-yl)methyl)benzoic acid(420846-72-6)
• EPA Substance Registry System: 3-((4-Oxo-3,4-dihydrophthalazin-1-yl)methyl)benzoic acid(420846-72-6)

Safety Data

• Hazardous Substances Data: 420846-72-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
3-((4-Oxo-3,4-dihydrophthalazin-1-yl)methyl)benzoic acid is used as a key intermediate in the synthesis of pharmaceuticals for its ability to contribute to the development of new drugs. Its structural properties allow for versatile chemical modifications, which can enhance the pharmacological profiles of resulting compounds.
Used in Organic Chemistry:
In the field of organic chemistry, 3-((4-Oxo-3,4-dihydrophthalazin-1-yl)methyl)benzoic acid serves as a building block for the creation of various organic compounds. Its reactivity and functional groups enable it to participate in a range of chemical reactions, facilitating the synthesis of complex organic molecules with specific applications.
Further research and development of 3-((4-Oxo-3,4-dihydrophthalazin-1-yl)methyl)benzoic acid may lead to its broader application in the medical and pharmaceutical industries, potentially contributing to the discovery of novel therapeutic agents and chemical entities with diverse uses.

Upstream product

• 119-67-5 o-carboxybenzaldehyde 
• 61260-15-9 dimethyl (3-oxo-1,3-dihydroisobenzofuran-1-yl)phosphonate 
• 763114-22-3 3-(1,3-dioxo-2,3-dihydro-1H-inden-2-yl)phenyl cyanide 
• 87-41-2 2-benzofuran-1(3H)-one 
• 24964-64-5 3-Cyanobenzaldehyde 
• 105-37-3 Ethyl propionate 
• 763114-23-4 3-(1,3-dioxoindan-2-yl)benzoic acid 
• 763114-24-5 2-[2-(3-carboxyphenyl)acetyl]benzoic acid 

Downstream Products

• 763111-46-2 4-[[3-(piperazine-1-carbonyl)phenyl]methyl]-2H-phthalazin-1-one 
• 1070772-18-7 4-[[3-(4-methylpiperazine-1-carbonyl)phenyl]methyl]-2H-phthalazin-1-one 
• 1070772-17-6 4-[[3-[4-(2-hydroxyethyl)piperazine-1-carbonyl]phenyl]methyl]-2H-phthalazin-1-one 
• 1070772-14-3 4-[[3-(4-phenylpiperazine-1-carbonyl)phenyl]methyl]-2H-phthalazin-1-one 
• 848136-81-2 4-[[3-(4-benzyl-1,4-diazepane-1-carbonyl)phenyl]methyl]-2H-phthalazin-1-one 
• 1070772-12-1 4-[[3-(4-pyrimidin-2-ylpiperazine-1-carbonyl)phenyl]methyl]-2H-phthalazin-1-one 
• 1431328-63-0 2,4-dinitrophenyl 4-[5-[(4-oxo-3H-phthalazin-1-yl)methyl]-benzoyl]piperazine-1-yl-1-ium-1,2-diolate 
• 26289-39-4 S-(2,4-dinitrophenyl)glutathione 
• 1174043-69-6 4-(3-(4-(cyclopentyloxy)piperidine-1-carbonyl)benzyl)phthalazin-1(2H)-one 
• 1174043-44-7 C₂₄H₂₇N₃O₃ 
• 1174043-73-2 4-(3-(4-ethoxypiperidine-1-carbonyl)benzyl)phthalazin-1(2H)-one 
• 1174043-74-3 4-(3-(4-methoxypiperidine-1-carbonyl)benzyl)phthalazin-1(2H)-one 
• 1174043-86-7 (4-(3-(4-((2-methylpropan-2-yl)oxy)piperidine-1-carbonyl)phenyl)methyl)-2H-phthalazin-1-one 
• 763114-27-8 1-[3-(4-oxo-3,4-dihydrophthalazin-l-ylmethyl)benzoyl]piperidine-4-carboxylic acid 

Relevant articles and documents

RADIOLABELLED COMPOUND

The present invention relates to radiolabelled olaparib and in particular [ 18 F]olaparib, a process for producing radiolabelled olaparib, and uses of radiolabelled olaparib in medical imaging.

HETEROCYCLIC-IMIDAZOLE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF

The present invention relates to a heterocyclic-imidazole derivative, a preparation method therefor, and a medical use thereof, and particularly to a new heterocyclic-imidazole derivative of general Formula (I), a preparation method therefor, a pharmaceutical composition comprising the same, and use thereof as a therapeutic agent, particularly as a poly(ADP-ribose)polymerase (PARP) inhibitor.

Heterocycle and imidazole compounds, pharmaceutical composition comprising heterocycle and imidazole derivatives as well as preparation method and application of heterocycle and imidazole compounds

The invention relates to heterocycle and imidazole derivatives as well as a preparation method and a pharmaceutical application of heterocycle and imidazole derivatives, in particular to novel heterocycle and imidazole derivatives as shown in the general formula (I), a preparation method of the heterocycle and imidazole derivatives, pharmaceutical composition comprising the heterocycle and imidazole derivatives as well as an application of the heterocycle and imidazole derivatives as a therapeutic agent and particularly as a PARP (poly (ADP-ribose) polymerase) inhibitor.

4-[3-(4-Cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl] -2H-phthalazin-1-one: A novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1

Poly(ADP-ribose) polymerase activation is an immediate cellular response to metabolic-, chemical-, or ionizing radiation-induced DNA damage and represents a new target for cancer therapy. In this article, we disclose a novel series of substituted 4-benzyl-2H-phthalazin-1-ones that possess high inhibitory enzyme and cellular potency for both PARP-1 and PARP-2. Optimized compounds from the series also demonstrate good pharmacokinetic profiles, oral bioavailability, and activity in vivo in an SW620 colorectal cancer xenograft model. 4-[3-(4-Cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl] -2H-phthalazin-1-one (KU-0059436, AZD2281) 47 is a single digit nanomolar inhibitor of both PARP-1 and PARP-2 that shows standalone activity against BRCA1-deficient breast cancer cell lines. Compound 47 is currently undergoing clinical development for the treatment of BRCA1- and BRCA2-defective cancers.

Phthalazinones 2: Optimisation and synthesis of novel potent inhibitors of poly(ADP-ribose)polymerase

We have previously described the discovery of poly(ADP-ribose)polymerase-1 (PARP-1) inhibitors based on a phthalazinone scaffold. Subsequent optimisation of inhibitory activity, metabolic stability and pharmacokinetic parameters has led to a novel series of meta-substituted 4-benzyl-2H-phthalazin-1-one PARP-1 inhibitors which retain low nM cellular activity and show good stability in vivo and efficacy in cell based models.

Phthalazinone derivatives

Compounds of the formula (I): wherein A and B together represent an optionally substituted, fused aromatic ring; X can be NRX or CRXRY; if X═NRX then n is 1 or 2 and if X═CRXRY then n is 1; RX is selected from the group consisting of H, optionally substituted C1-20 alkyl, C5-20 aryl, C3-20 heterocyclyl, amido, thioamido, ester, acyl, and sulfonyl groups; RY is selected from H, hydroxy, amino; or RX and RY may together form a spiro-C3-7 cycloalkyl or heterocyclyl group; RC1 and RC2 are both hydrogen, or when X is CRXRY, RC1, RC2, RX and RY, together with the carbon atoms to which they are attached, may form an optionally substituted fused aromatic ring; and R1 is selected from H and halo.

PHTHALAZINONE DERIVATIVES

Compounds of the formula (I): wherein A and B together represent an optionally substituted, fused aromatic ring; X can be NRX or CRXRY; if X NRX then n is 1 or 2 and if X = CRXRY then n is 1; RX is selected from the group consisting of H, optionally substituted C1-20 alkyl, C5-20 aryl, C3-20 heterocyclyl, amido, thioamido, ester, acyl, and sulfonyl groups; RY is selected from H, hydroxy, amino; or RX and RY may together form a spiro-C3-7 cycloalkyl or heterocyclyl group; RC1 and RC2 are both hydrogen, or when X is CRX RY, RC1, RC2, RX and RY, together with the carbon atoms to which they are attached, may form an optionally substituted fused aromatic ring; and R1 is selected from H and halo.